Midatech Pharma PLC-ADR MTP shares were trading higher Friday after the company announced positive results from a first-in-human study of its MTX102 immuno-tolerizing vaccine product candidate in diabetes.
The results showed that MTX102 was well-tolerated, with asymptomatic local injection site reactions being the only drug-related finding, and no serious adverse events were reported, according to Midatech.
“This EU-funded program is an invaluable project to further develop, understand and evaluate Midatech’s gold nanoparticle technology, MidaCore,” CEO Craig Cook said in a statement.
"This is the first human study to assess the safety of MidaCore when injected into patients, and we are pleased that the data generated to date validates the technology as a potentially innovative treatment platform for medical applications."
Midatech shares were trading higher by 45.38% at $1.89 at the time of publication Friday. The stock has a 52-week high of $10.90 and a 52-week low of $1.03.
Related Links:
Eton Pharmaceuticals Shares Slammed After FDA Complete Response Letter
Neon Therapeutics Shares Higher After Positive Cancer Vaccine Study
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
